A prospective evaluation of lung function at three and six months in patients with previous SARS-COV-2 pneumonia.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
09 2021
Historique:
received: 10 04 2021
revised: 11 06 2021
accepted: 08 07 2021
pubmed: 20 7 2021
medline: 9 10 2021
entrez: 19 7 2021
Statut: ppublish

Résumé

This study investigated the consequences of Coronavirus Disease 2019 (COVID-19) pneumonia on lung function in the first 6 months after hospital discharge. A prospective lung function assessment in SARS-CoV2 patients with COVID-19 pneumonia, hospitalized between March and April 2020, was conducted with spirometry measurements including lung volumes, mainly total lung capacity (TLC), lung diffusion capacity for carbon monoxide (DL Among 40 consecutive patients, 19 (48%) had normal pulmonary functional tests (group A), and 21 (52%) showed residual lung function abnormalities at 3 months after hospital discharge (group B). In group B, 4 patients (19%) had only loss of lung volume as shown by TLC reduction (group 1), 13 patients (62%) had decreased both TLC and DL Nearly 50% of patients recovered in the post-critical phase. Most of those with abnormal pulmonary function tests at 3 months improved subsequently, but only another 29% (6 out of 21) reached normal values at 6 months. These results indicate that lung function spontaneous recovery is faster at first and occurs more slowly thereafter, leaving more than one third (15 out of 40) of patients with abnormal lung function tests at 6 months.

Identifiants

pubmed: 34280885
pii: S0954-6111(21)00247-X
doi: 10.1016/j.rmed.2021.106541
pmc: PMC8272067
pii:
doi:

Substances chimiques

Biosimilar Pharmaceuticals 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

106541

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Curr Med Sci. 2020 Apr;40(2):275-280
pubmed: 32207032
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Allergy. 2021 Mar;76(3):961-962
pubmed: 33675253
JAMA. 2020 Apr 14;323(14):1335
pubmed: 32181795
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Respir Res. 2020 Jun 29;21(1):163
pubmed: 32600344
Respir Med. 2021 Jan;176:106272
pubmed: 33302142
Respir Med. 2021 Jan;176:106261
pubmed: 33260107
Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):177-179
pubmed: 32308940
Int J Infect Dis. 2020 Apr;93:284-286
pubmed: 32145466
Allergy. 2021 Mar;76(3):887-892
pubmed: 32738147
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-415
pubmed: 32271722
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702

Auteurs

Nicla Orzes (N)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Laura Pini (L)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Respiratory Medicine Unit, Spedali Civili di Brescia, Brescia, Italy. Electronic address: laura.pini@unibs.it.

Guido Levi (G)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Silvia Uccelli (S)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Francesca Cettolo (F)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Claudio Tantucci (C)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Respiratory Medicine Unit, Spedali Civili di Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH